"Oligometastatic pancreatic cancer" definition: The first step

Pancreatic ductal adenocarcinoma(PDAC)is nowadays the fourth leading cause of cancer-related death worldwide,but ac-cording to recent estimations it will become the second leading cause of cancer-related deaths in the USA up to 2030,follow-ing lung cancer.The implementation of neoadjuvant chemother-apy during recent years led to an increase of overall survival at 35 months in PDAC after R0 resection[1].However,pancreatic cancer has a particularity that makes it a real challenge for clinicians:only 20％of patients are diagnosed early enough to have a resectable pancreatic cancer,whereas 40％of patients present with locally ad-vanced or non-resectable disease,while the rest present with dis-tant metastases[2].Systemic chemotherapy plays the main role in metastatic PDAC treatment:polychemotherapy regimens such as FOLFIRINOX(folinic acid,5-fluorouracil,irinotecan and oxaliplatin)or combination of gemcitabine/nab-paclitaxel seemed to improve median overall survival from 6.8 to 11.1 months and 6.7 to 8.5 months,respectively[3].